

**Supplementary Table 1.** Baseline characteristics of matched patients

Variable	Pancreaticoduodenectomy (n=72)	Distal pancreatectomy (n=72)	P value
Age, yr	61.7±11.5	59.7±13.5	0.322
Male sex	40 (55.6)	37 (51.4)	0.120
Body mass index, kg/m <sup>2</sup>	23.7±2.9	24.2±3.1	0.312
HbA1c, %	6.2±1.6	6.2±1.2	0.901
Glucose at 0 min, mg/dL	120.1±47.0	114.3±33.4	0.393
Glucose at 60 min, mg/dL	228.8±79.1	218.5±74.6	0.425
Glucose at 120 min, mg/dL	209.4±103.5	194.3±89.1	0.349
AUC <sub>Glucose</sub>	393.5±147.3	372.8±129.2	0.371
Insulin at 0 min, µIU/mL	8.6±4.2	9.1±3.8	0.383
Insulin at 60 min, µIU/mL	49.9±46.8	51.5±39.3	0.828
Insulin at 120 min, µIU/mL	56.6±50.4	53.7±44.9	0.721
AUC <sub>Insulin</sub>	82.5±62.3	83.0±54.4	0.965
C-peptide, ng/mL	2.8±1.6	2.4±1.2	0.116
HOMA-IR	2.6±2.0	2.5±1.2	0.762
HOMA-β	70.2±40.9	81.5±56.3	0.172
Matsuda ISI	5.8±4.9	5.5±5.0	0.735
IGI <sub>60</sub>	17.3±65.1	27.9±64.4	0.331
Disposition index	10.4±28.2	12.0±38.3	0.778
Total cholesterol, mg/dL	193.6±57.2	179.6±35.0	0.082
Aspartate aminotransferase, IU/L	64.4±81.1	23.9±10.2	<0.001
Alanine aminotransferase, IU/L	88.5±121.4	22.7±15.5	<0.001
Creatinine, mg/dL	0.70±0.21	0.75±0.20	0.124
eGFR, mL/min/1.73 m <sup>2</sup>	98.4±14.9	95.6±14.2	0.24
hsCRP, mg/L	0.70±1.26	0.80±3.55	0.833
Resected pancreas volume, cm <sup>3</sup>	110.2±60.4	104.9±80.9	0.657
Pathology (pancreatic cancer)	35 (48.6)	40 (55.6)	0.505
ASA PS classification			0.120
Class I	17 (23.6)	20 (27.8)	
Class II	50 (69.4)	40 (55.6)	
Class III	5 (6.9)	12 (16.7)	
Comorbidities			
Prediabetes	15 (20.8)	19 (26.4)	0.556
Diabetes mellitus	20 (27.8)	22 (30.6)	0.855
Hypertension	31 (43.1)	30 (41.7)	0.999
Dyslipidemia	26 (36.1)	26 (36.1)	1.000
Obesity	20 (27.8)	26 (36.1)	0.372
Nephropathy	1 (1.4)	1 (1.4)	1.000
Preoperative medications			
Antidiabetic agents	16 (22.2)	20 (27.8)	0.564
Antihypertensive agents	29 (40.3)	30 (41.7)	0.999
Lipid-lowering agents	17 (23.6)	23 (31.9)	0.352
Neoadjuvant chemotherapy <sup>a</sup>	5 (6.9)	6 (8.3)	0.999
Postoperative chemotherapy	34 (47.2)	32 (44.4)	0.867

Values are presented as mean ± standard deviation or number (%).

HbA1c, glycosylated hemoglobin; AUC, area under curve; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell function; ISI, insulin sensitivity index; IGI, insulinogenic index; eGFR, estimated glomerular filtration rate; hsCRP, high-sensitivity C-reactive protein; ASA, American Society of Anesthesiologists; PS, performance status.

<sup>a</sup>All patients were treated with FOLFIRINOX combination chemotherapy (oxaliplatin, irinotecan, leucovorin, and fluorouracil).